Ethical committee approval will be obtained from Ethics committee of Faculty of Pharmacy, Damanhour University.~Ethical committee approval will be obtained from Ethics committee of General Organization for Teaching Hospitals and Institutes.~About 50 patients who are candidate to detect the hepato-protective effect of Dapagliflozin on non- alcoholic fatty disease, will be recruited from Alexandria Teaching Hospital (EL-Mery), General Organization for Teaching Hospitals and Institutes.~All participants should agree to take part in this clinical study and will provide informed consent.~Demographic data; age (year), sex (female/male), weight (kg), height (cm), BMI (kg/m2) will be collected.~Venous blood samples (5 ml will be collected by a sterile syringe then placed in a suitable sterile tube to be centrifuged, the serum will be reserved and stored at -80°C until the analysis) before, and after receiving medication (Dapagliflozin).~Measuring outcome:~The biochemical tests will be done on the patients are alanine aminotransferase (ALT), aspartate aminotransferase (AST), homeostasis model assessment of insulin resistance (HOMA-IR), Hemoglobin A1C (HbA1C), Low-density lipoproteins (LDL), High-density lipoproteins (HDL), Triglycerides (TG), liver fibrosis score, and complete blood count (CBC).~The molecular tests will be done on the patient are soluble vascular cell adhesion molecule-1 (Svcam-1), adipocytes (e.g. adiponectin, leptin).~The ultrasound screening will be done at first examination.~Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results.~Results, conclusion, discussion and recommendations will be given.
The aim of this study is to evaluate the effect of dapagliflozin on liver function of patient with NAFLD and T2DM.